Publisher
Springer Science and Business Media LLC
Reference18 articles.
1. Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F; CombAT Study Group (2010) The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 57: 123–131
2. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G (2002) Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 60:434–441
3. Takamori H, Masumori N, Kamoto T (2017) Surgical procedures for benign prostatic hyperplasia: a nationwide survey in Japan, 2014 update. Int J Urol 24:476–477
4. Wada N, Kita M, Hashizume K, Matsumoto S, Kakizaki H (2013) Urodynamic effects of dutasteride add-on therapy to alpha-adrenergic antagonist for patients with benign prostatic enlargement: prospective pressure-flow study. Neurourol Urodyn 32:1123–1127
5. Wada N, Hashidume K, Tamaki G, Kita M, Iwata T, Matsumoto S, Kakizaki H (2012) Add-on effect of dutasteride in patients with benign prostatic hyperplasia treated with alpha blocker: its effect on overactive bladder. Act Urol Jpn 58:475–480
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献